Antibodies
20 December 2010
Peregrine Completes Treatment of Last Patient in Phase II Cotara(R) Brain Cancer Trial14 December 2010
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer14 December 2010
Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer14 December 2010
Life Science Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of ABT-806 for the Treatment of Cancer14 December 2010
Compugen Announces Positive Therapeutic Effect of CGEN-15001 in Animal Model of Rheumatoid Arthritis14 December 2010
UCB Announces Start of Phase III Program With Epratuzumab for Patients With Moderate to Severe Systemic Lupus Erythematosus13 December 2010
ImmunoGen, Inc. Announces Clinical Data for T-DM1 Used in Combination with Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer9 December 2010
VELCADE Induction Followed by VELCADE Maintenance Improves Clinical Outcomes in Previously Untreated Multiple Myeloma Patients7 December 2010
Halozyme Announces Roche Completes Patient Enrollment in Phase 3 Clinical Trial with Subcutaneous Herceptin6 December 2010
Micromet’s Blinatumomab Produces High Objective Response Rate in Spectrum of Relapsed Non-Hodgkin’s Lymphoma Patients6 December 2010
Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology MeetingNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports